ArticlePhytotherapy research : PTR2026
Amentoflavone, a Preferentially TGF-β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF-β/Smad and MAPK Signaling Pathways.
Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alogliptin/Amentoflavone Combination Mitigates Bleomycin-Induced Lung Fibrosis: The Role of Oxidative Stress, TXNIP-Mediated Pyroptosis, and Autophagy/Apoptosis Balance.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Chronic cardiac stress induces cardiac hypertrophy and fibrosis, thereby promoting pathological heart remodeling, which is the core pathological process of heart failure. Amentoflavone (AMF) has beneficial therapeutic effects against several cardiovascular diseases; however, its role and underlying mechanisms in pathological cardiac remodeling remain unclear. Here, we investigated the protective role of AMF against pathological cardiac remodeling in transverse aortic constriction (TAC)-induced overloaded hearts. Mice with pressure overload caused by TAC were treated with AMF, and the effects of AMF on cardiac function, cardiac hypertrophy, and fibrosis were analyzed. RNA-seq, molecular docking, surface plasmon resonance (SPR), and co-IP were used to identify the downstream targets of AMF. Angiotensin II (Ang II) and transforming growth factor beta 1 (TGF-β1) were used to characterize the role of AMF and its downstream targets in cardiac hypertrophy and fibrosis in vitro. Sustained AMF administration significantly suppressed TAC-induced cardiac remodeling. Compared with those in TAC model mice, the heart/body weight ratio, cardiomyocyte cross-sectional area, and hypertrophic molecular markers were significantly lower in AMF-treated TAC model mice. Moreover, TAC-induced myofibroblast generation and extracellular matrix deposition were effectively reversed following AMF administration. Similar results were obtained after AMF treatment for cardiomyocyte hypertrophy and cardiac fibrosis in vitro. Mechanistically, by directly binding to TGF-β receptor 1, AMF blocked the regulatory effect of TGF-β1 and inhibited the TGF-β/Smad and MAPK signaling pathways. These results suggest that AMF, through binding to TGF-β receptor 1, may be a promising therapeutic option for pathological cardiac remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.